References
- Adams J., Polson D. W., Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br. Med. J. 1986; 293: 355–9
- Kirschner M. A., Zucker I. R., Jespersen D. Idiopathic hirsutism ‐ an ovarian abnormality. N. Engl. J. Med. 1976; 294: 637–40
- Senöz S., Özaksit G., Turhan N. Ö., Gülekli B., Çaĝlar T., Gökmen O. Lipid profiles in women with hirsutism and polycystic ovaries. Gxsynecol. Endocrinol. 1994; 8: 33–7
- Ferriman D., Gallwey J. D. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 1961; 21: 1440–8
- Givens J. R., Anderson R. N., Wiser W. L., Umstot E. S., Fish S. A. The effectiveness of two oral contraceptives in supressing plasma androstenedione, testosterone, LH and FSH and in stimulating plasma testosterone binding capacity in hirsute women. Am. J. Obstet. Gynecol. 1976; 124: 333–9
- Barth J. H., Cherry C. A., Wojnarowska F., Dawber R. P. R. Cyproterone acetate for severe hirsutism: results of a double‐blind dose‐ranging study. Clin. Endocrinol. 1991; 35: 5–10
- Barth J. H., Cherry C. A., Wojnorowska F., Dawber R. P. R. Spironolactone is an effective and well tolerated systemic anti‐androgen therapy for hirsute women. J. Chi. Endocrinol. Metab. 1989; 68: 966–70
- Vidal P. A. J., Munoz T. M., Jodar G. E., Garcia C. C. J., Lardelli P., Ruiz D. M. E., Escobar J. F. Ketaconazole therapy: hormonal and clinical effects in non‐tumoral hyperandrogenism. Eur. J. Endocrinol. 1994; 130: 333–8
- Serafini P., Lobo R. A. The effects of spironolactone on adrenal steroidogenesis in hirsute women. Fertil. Steril. 1985; 44: 595
- Young R. L., Goldzieher J. W., Elkind‐Hirsch K. The endocrine effects of spironolactone used as an antiandrogen. Fertil. Steril. 1987; 48: 223–8
- Weidmann P., Gerber A. Effects of treatment with diuretics on serum lipoproteins. J. Cardiovasc. Pharmacol. 1984; 6: S260–268, Suppl
- Venturoli S., Fabbri R., Dal Prato L., Mantovani B., Capelli M., Magrini O., Flamigni C. Ketaconazole therapy for women with acne and/or hirsutism. J. Clin. Endocrinol. Metab. 1990; 71: 335–9
- Sobel J. D. Management of recurrent vulvovaginal candidiasis with intermittant ketaconazole prophylaxis. Obstet. Gynecol. 1985; 65: 435–40
- Lewis J. H., Zimmerman H. J., Benson G. D., Ishak K. G. Hepatic injury associated with ketaconazole therapy. Gastroenter ology 1984; 86: 503–5
- Martikainen H., Heikkinen J., Roukonen A., Kauppila A. Hormonal and clinical effects of ketoconazole in hirsute women. J. Chi. Endocrinol. Metab. 1988; 66: 987–91
- Henkin Y., Como J. A., Oberman A. Secondary dyslipidemia: inadvertent effects of drugs in clinical practice. J. Am. Med. Assoc. 1992; 267: 961–8
- Gülekli B., Turhan N. Ö., Senöz S., Kükner S., Oral H., Gökmen O. Endocrinological, ultrasonographic and clinical findings in adolescent and adult polycystic ovary patients: a comparative study. Gynecol. Endocrinol. 1993; 7: 273–7
- Conway G. S., Agrawal R., Betteridge D. J., Jacobs H. S. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin. Endocrinol. 1992; 37: 119–25